Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe entities : Gilead sciences, inc. save search
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Published: 2023-10-18 (Crawled : 11:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.01%
H: 0.3%
C: -0.99%
europe sciences hiv program trial
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Published: 2022-09-16 (Crawled : 12:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
yescarta europe chmp t-cell positive therapy
Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of European Crohn's and Colitis Organization (ECCO)
Published: 2022-02-18 (Crawled : 18:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.18%
H: 0.42%
C: -0.57%
treatment europe disease preclinical potential pre-clinical
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Published: 2021-12-21 (Crawled : 11:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.0%
H: 0.17%
C: -0.87%
covid-19 treatment europe risk oxygen covid disease
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Published: 2021-12-07 (Crawled : 10:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
europe covid covid-19
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
Published: 2021-11-15 (Crawled : 16:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.34%
H: 1.74%
C: -0.4%
treatment europe ulcerative colitis
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
Published: 2021-08-19 (Crawled : 23:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.49%
H: 1.01%
C: 0.08%
treatment europe therapy hiv authorized xin
Gilead Sciences to Acquire MYR GmbH
Published: 2020-12-10 (Crawled : 14:01) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.26%
H: 0.39%
C: -0.35%
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.